long term use of semaglutide Weight-loss drugs are becoming more accessible, but are they always safe? Experts raise concerns about the misuse generics and the risks of unsupervised use. From side effects to long-term impact Ready to lose weight without

Your provider can recommend the best combination for you

Some drugs experienced continued growth in 2022: multiple sclerosis drug Ocrevus (ocrelizumab) had a 17 percent increase in sales, sales of hemophilia A therapy Hemlibra (emicizumab) increased by 27 percent and sales of cancer treatment Tecentriq (atezolizumab) increased by 14 percent

Intriguingly, some clues suggest a GLP-1 sensitizing action of metformin in pancreatic -cells

And the newest entrant, retatrutide a triple agonist hitting GLP-1, GIP, and glucagon receptors achieved 28.7% body weight loss in its Phase 3 TRIUMPH-4 trial (published December 2025)